Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403

Benzinga Newsdesk www.benzinga.com Negative 82.0%

Neg 82% Neu 0% Pos 0%

Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and lowers the price target from $409 to $403.